Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 1739

Next Previous
Drug Profile

CX 1739

Alternative Names: CX-1739

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute of Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias; Behavioural disorder therapies; Drug withdrawal therapies; Mood stabilisers; Respiratory stimulants; Sleep disorder therapies
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory insufficiency; Sleep apnoea syndrome; Spinal cord injuries
  • Discontinued Attention-deficit hyperactivity disorder; Substance-related disorders

Most Recent Events

  • 17 Oct 2025 Phase-II clinical trials in Spinal cord injuries (PO) (prior to October 2025) (RespireRx pipeline, October 2025)
  • 29 May 2024 RespireRx Pharmaceuticals plans a phase-IIA/B trial in Spinal cord injuries in 4Q 2024
  • 29 May 2024 RespireRx Pharmaceuticals plans to file an IND application for phase II trial in Spinal cord injuries prior to 4Q 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top